Invention Grant
- Patent Title: Procoagulant fusion compound
-
Application No.: US15035145Application Date: 2014-11-07
-
Publication No.: US10584147B2Publication Date: 2020-03-10
- Inventor: Karina Thorn
- Applicant: Bioverativ Therapeutics Inc.
- Applicant Address: US MA Waltham
- Assignee: Biovertiv Therapeutics Inc.
- Current Assignee: Biovertiv Therapeutics Inc.
- Current Assignee Address: US MA Waltham
- Agency: Lathrop GPM LLP
- Agent James H. Velema, Esq.
- International Application: PCT/US2014/064541 WO 20141107
- International Announcement: WO2015/070014 WO 20150514
- Main IPC: C07K14/745
- IPC: C07K14/745 ; C07K14/00 ; A61K38/00

Abstract:
The present invention provides a fusion compound comprising a procoagulant compound and an immunoglobulin constant region or a portion thereof and methods of making and using the fusion compound. The fusion compounds of the present disclosure are useful for the treatment of coagulation disorders, such as hemophilia. In some aspects, the invention includes a method of reducing or preventing aggregates which comprise a procoagulant compound comprising fusing the procoagulant compound to an immunoglobulin constant region or a portion thereof wherein the procoagulant compound comprises an amino acid sequence. In another embodiment, the fusion compound forms less aggregates compared to a compound consisting of the procoagulant compound.
Public/Granted literature
- US20160289273A1 PROCOAGULANT FUSION COMPOUND Public/Granted day:2016-10-06
Information query